Ironwood Pharmaceuticals (IRWD) Trading -0.2% Higher

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s share price traded up 0.2% on Wednesday . The stock traded as high as $14.25 and last traded at $14.04. 486,099 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 2,002,413 shares. The stock had previously closed at $14.07.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Credit Suisse Group assumed coverage on Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a “buy” rating and a $19.00 target price on the stock. ValuEngine lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Mizuho lowered Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $20.00 to $16.00 in a report on Wednesday, December 6th. Finally, BidaskClub lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $17.56.

The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86. The firm has a market capitalization of $2,111.55, a PE ratio of -14.09 and a beta of 1.29.

In other Ironwood Pharmaceuticals news, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the completion of the sale, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total value of $927,000.00. Following the completion of the sale, the insider now owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,905 shares of company stock valued at $2,666,359. 7.63% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Ironwood Pharmaceuticals by 128.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock worth $135,000 after buying an additional 5,069 shares during the period. Gerber Kawasaki Wealth & Investment Management bought a new position in Ironwood Pharmaceuticals during the 3rd quarter worth about $170,000. Ameritas Investment Partners Inc. increased its holdings in Ironwood Pharmaceuticals by 5.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 648 shares in the last quarter. Hemenway Trust Co LLC bought a new position in Ironwood Pharmaceuticals during the 4th quarter worth about $204,000. Finally, Virtu KCG Holdings LLC increased its holdings in Ironwood Pharmaceuticals by 10.3% during the 2nd quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after purchasing an additional 1,470 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2018/02/09/ironwood-pharmaceuticals-irwd-trading-0-2-higher.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit